An analysis tool for exploration/visualization of the impact of expected values (CV, theta0, reduced sample size due to drop-outs) on power of BE decision via scABE for narrow therapeutic drugs (NTIDs) if these values deviate from the ones assumed in planning the sample size of the study. The only implemented design is the full replicate design "2x2x4" according to the FDA Warfarin guidance.
pa.NTIDFDA(CV, theta0 = 0.975, targetpower = 0.8, minpower = 0.7, ...)Coefficient of variation of the intra-subject variabilities of Test and Reference as ratio. Here only the case CVwT=CVwR is implemented, i.e. CV has to be a scalar.
‘True’ or assumed T/R ratio. Often named GMR. Must be given as ratio. Defaults here to 0.975.
Power to achieve at least in sample size estimation. Must be >0 and <1. Typical values are 0.8 or 0.9. Defaults to 0.8. Note that targetpower < 0.5 doesn<U+2019>t make much sense.
Minimum acceptable power to have if deviating from assumptions for sample size plan.
Has to be lower than targetpower. Defaults to 0.7.
minpower < 0.5 doesn<U+2019>t make much sense.
More arguments to pass to power.NTIDFDA().
F.i. alpha, theta1, theta2 or nsims if other values
then the defaults for these arguments are needed.
See man page of power.NTIDFDA().
Returns a list with class 'pwrA' with the components
A data.frame with the result of the sample size estimation.
See output of sampleN.NTIDFDA().
A data.frame with value pairs CV, pwr for impact of deviations from CV.
A data.frame with value pairs theta0, pwr for impact of deviations from theta0 (GMR).
A data.frame with value pairs N, pwr for impact of deviations from planned N (dropouts).
Method of BE decision. Here fix = "NTID FDA".
Here fix = "FDA".
Minimum acceptable power from the call of the function.
The class 'pwrA' has the S3 methods print() and plot(). See pa.ABE for usage.
Be extremly carefull if your sample size plan has extremly small CV near or
below 0.05 (5%). Adapt in that case your expected true ratio (theta0)
to values nearer to 1 to not run into errors and/or long execution times.
Power calculations are done via power.NTIDFDA() and
calculations of CV and theta0 which result in minpower are derived via uniroot().
While one of the parameters (CV, theta0, n) is varied, the respective two others are
kept constant. The tool shows the relative impact of single parameters on power.
The tool takes a minimum of 12 subjects into account as demanded in most BE guidances.
However, it should be kept in mind that the FDA requires at least 24 subjects to be enrolled
in studies intended for reference-scaling.
It should be kept in mind that this is not a substitute for the “Sensitivity Analysis”
recommended in ICH-E9. In a real study a combination of all effects occurs simultaneously.
It is up to you to decide on reasonable combinations and analyze their respective power.
FDA. Draft Guidance on Warfarin Sodium. Recommended Dec 2012 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201283.pdf
Yu LX et al. Novel bioequivalence approach for narrow therapeutic index drugs Clin Pharmacol Ther. 2015;97(3):286--91. 10.1002/cpt.28
Jiang W et al. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion AAPS J. 2015;17(4):891--901. 10.1208/s12248-015-9753-5
Endr<U+00E9>nyi L, T<U+00F3>thfalusi L. Determination of Bioequivalence for Drugs with Narrow Therapeutic Index: Reduction of the Regulatory Burden J Pharm Pharm Sci. 2013;16(5):676--82. free download
# NOT RUN {
# using the defaults:
# targetpower=0.8, minpower=0.7, theta0/GMR=0.975
# BE margins from defaults of sampleN.NTIDFDA() 0.9002 ... 1.1108
# 1E5 sims in power.NTIDFDA()
# not run due to timing policy of CRAN for examples
# may run some ten seconds or more
# }
# NOT RUN {
plot(pa.NTIDFDA(CV=0.1))
# }
Run the code above in your browser using DataCamp Workspace